Journal of Clinical Oncology, Vol 12, 1859-1867, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery

MM Heiss, W Mempel, C Delanoff, KW Jauch, C Gabka, M Mempel, HJ Dieterich, HJ Eissner and FW Schildberg
Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany.

PURPOSE: Allogeneic blood transfusions have reportedly been associated with a poor prognosis in patients with curatively resected cancer. To control for immunosuppression induced by a speculatively causal allogeneic blood transfusion, we designed a randomized study in which the control group received autologous blood transfusions not related to any condition of immunosuppression. PATIENTS AND METHODS: One hundred twenty patients with potentially curative resectable colorectal cancer and the capability to predeposit autologous blood were randomly selected to receive either standard allogeneic blood transfusion or predeposited autologous blood. RESULTS: In curatively resected cancer patients, the number who needed allogeneic blood transfusions was reduced from 60% in the allogeneic blood group to 33% in the autologous blood group (P = .009). After a median follow-up duration of 22 months (range, 8 to 48) tumor recurrence was observed in 28.9% of the allogeneic blood group and 16.7% of the autologous blood group. Life- table analysis established a tendency toward a shorter tumor-free survival for the allogeneic blood group (log-rank P = .11). The problem with this analysis was the strong association of allogeneic blood transfusions with tumor recurrence, which interfered in 33% of patients in the autologous blood group who required additional allogeneic blood transfusions. Multivariate analysis of established risk factors for tumor recurrence and surgery-related variables reflecting potential immunosuppressive conditions showed that only pT stage (relative risk, 6.61; 95% confidence interval [CI], 1.82 to 23.99; P = .004), pN stage (relative risk, 8.39; 95% CI, 3.15 to 22.33; P < .001), and the need for allogeneic blood (relative risk, 6.18; 95% CI, 2.20 to 17.37; P < .001) were independent predictors of tumor recurrence. Subgroup analysis of patients who received a transfusion of < or = 2 U blood found a significantly higher risk of tumor recurrence in the allogeneic blood group (relative risk, 5.16; 95% CI, 1.13 to 23.62; P = .034), which was reduced to borderline significance (relative risk, 3.54; 95% CI, 0.76 to 16.51; P = .107) by adjustment for tumor (T) and node (N) stage. CONCLUSION: As indicated by these first results, the blood transfusion modality has a significant effect on tumor recurrence after surgical treatment of colorectal cancer. A change in the practice of blood transfusion might thus potentially surpass the impact of any recent adjuvant treatment strategies.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. K. Kazanjian, O. J. Hines, J. P. Duffy, D. Y. Yoon, G. Cortina, and H. A. Reber Improved Survival Following Pancreaticoduodenectomy to Treat Adenocarcinoma of the Pancreas: The Influence of Operative Blood Loss Arch Surg, December 1, 2008; 143(12): 1166 - 1171. [Abstract] [Full Text] [PDF]

				T. Steinmetz, M. Hellmich, M. Neise, A. Aldaud, C. Lerchenmuller, A. Tsamaloukas, F. Fandel, C. Weiligmann, U. Totzke, and S. Schmitz Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors Oncologist, June 1, 2007; 12(6): 748 - 755. [Abstract] [Full Text] [PDF]

				N. Jabbour, S. Gagandeep, H. Shah, R. Mateo, M. Stapfer, Y. Genyk, L. Sher, M. Zwierzchoniewska, R. Selby, and G. Zeger Impact of a Transfusion-Free Program on Non-Jehovah's Witness Patients Undergoing Liver Transplantation Arch Surg, September 1, 2006; 141(9): 913 - 917. [Abstract] [Full Text] [PDF]

				B. D. Spiess Transfusion of Blood Products Affects Outcome in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 267 - 281. [Abstract] [PDF]

				W. Rzyman, R. Dziadziuszko, J. Skokowski, R. Wilimski, A. Raiter, A. Szymanowska, and J. Jassem The influence of blood transfusion on survival in operated non-small cell lung cancer patients J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 755 - 760. [Abstract] [Full Text] [PDF]

				M. Nosotti, P. Rebulla, D. Riccardi, A. Baisi, N. Bellaviti, L. Rosso, and L. Santambrogio Correlation Between Perioperative Blood Transfusion and Prognosis of Patients Subjected to Surgery for Stage I Lung Cancer Chest, July 1, 2003; 124(1): 102 - 107. [Abstract] [Full Text] [PDF]

				B. D. Speiss Transfusion and outcome in heart surgery Ann. Thorac. Surg., October 1, 2002; 74(4): 986 - 987. [Full Text] [PDF]

				E. S Vanderlinde, J. M Heal, and N. Blumberg Autologous transfusion BMJ, March 30, 2002; 324(7340): 772 - 775. [Full Text] [PDF]

				H.-S. Lin, R. N. Samy, J. Lum, M. J. Dorie, and D. J. Terris Effect of Blood Transfusion in an Experimental Sarcoma Model Arch Otolaryngol Head Neck Surg, March 1, 2002; 128(3): 308 - 312. [Abstract] [Full Text] [PDF]

				B. D. Spiess Blood transfusion: the silent epidemic Ann. Thorac. Surg., November 1, 2001; 72(5): S1832 - 1837. [Abstract] [Full Text] [PDF]

				G. Nicol, E. Hunt, and M. Manji When to give blood Trauma, October 1, 2001; 3(4): 221 - 233. [Abstract] [PDF]

				C.-F. C. Sun, Y.-Y. Hsieh, K.-W. Ngan, and W.-T. Wang Search for Immunomodulatory Effects of Blood Transfusion in Gastric Cancer Patients: Flow Cytometry of Th1/Th2 Cells in Peripheral Blood Ann. Clin. Lab. Sci., April 1, 2001; 31(2): 171 - 178. [Abstract] [Full Text] [PDF]

				E. C. Vamvakas and M. A. Blajchman Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood, March 1, 2001; 97(5): 1180 - 1195. [Full Text] [PDF]

				S. A. Kirkley Proposed Mechanisms of Transfusion-Induced Immunomodulation Clin. Vaccine Immunol., September 1, 1999; 6(5): 652 - 657. [Full Text] [PDF]

				L. T. Goodnough, M. E. Brecher, M. H. Kanter, and J. P. AuBuchon Transfusion Medicine -- Blood Transfusion- First of Two Parts N. Engl. J. Med., February 11, 1999; 340(6): 438 - 447. [Full Text] [PDF]

				D. Savarese, H. Waitkus, F. M. Stewart, and M. Callery Bloodless Medicine and Surgery J Intensive Care Med, January 1, 1999; 14(1): 20 - 33. [PDF]

				M. A. Forgie, P. S. Wells, A. Laupacis, D. Fergusson, and for the International Study of Perioperative Trans Preoperative Autologous Donation Decreases Allogeneic Transfusion but Increases Exposure to All Red Blood Cell Transfusion: Results of a Meta-analysis Arch Intern Med, March 23, 1998; 158(6): 610 - 616. [Abstract] [Full Text] [PDF]